DHSC extends SSPs for Fluoxetine 10mg tablets, Lipitor 10mg chewable tablets until December 7


Share post:

The Department of Health and Social Care (DHSC) has extended the Serious Shortage Protocols (SSPs) for Fluoxetine 10mg tablets (SSP005) and Lipitor 10mg chewable tablets (SSP032) to Wednesday, 7 December 2022.

SSP005 for Fluoxetine 10mg tablets was due to expire on 12 August 2022.

DHSC has also updated that SSP032 for Lipitor 10mg chewable tablets was due to expire on 12 August 2022 but the end date has been further extended to Friday 26 August 2022.

SSP005 provides that for every Fluoxetine 10mg tablet originally prescribed, one Fluoxetine 10mg capsule must be supplied:

For prescriptions (NHS or private) requesting: Supply permitted under SSP005: Current expiry date
Fluoxetine 10mg tablets Fluoxetine 10mg capsules This SSP has been varied – the revised end date for SSP005 is now Wednesday 7 December 2022

SSP032 provides that for every Lipitor® 10mg chewable tablet originally prescribed, either one Atorvastatin 10mg film-coated tablet or the equivalent dose of Atorvastatin 20mg/5ml oral suspension sugar free must be supplied.

For prescriptions (NHS or private) requesting: Supply permitted under SSP032: Current expiry date
Lipitor® 10mg chewable tablets Atorvastatin 10mg tablets
Atorvastatin 20mg/5ml oral suspension sugar free
This SSP has been varied – the revised end date for SSP032 is now Friday 26 August 2022


“Expiry dates of an SSP may be brought forward or extended, and the content may be amended at any time during the life of an SSP. Pharmacists should ensure they are using the latest version of an SSP before considering the supply of an alternative product,” said DHSC.

Current versions of SSPs can be found at: www.nhsbsa.nhs.uk/pharmacies-gp-practices-andappliance-contractors/serious-shortage-protocols-ssps


Please enter your comment!
Please enter your name here

Current Issue June 2023

Related articles

MHRA grants authorisation for LEO Pharma’s Adtralza 2 mL pen solution

The Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the marketing authorisation of Adtralza, a dermatological solution...

Grundon launches maiden UK-wide inhaler recycling programme

Grundon Waste Management has introduced what it claims to be the UK's first verified nationwide inhaler return and...

‘Record fine imposed on hydrocortisone manufacturers for dominant position abuse and 10,000% price increase’

The Competition Appeal Tribunal (CAT) has upheld the Competition and Markets Authority’s (CMA) findings against two pharmaceutical manufacturers...

Vision Report: Legal reforms, adequate funding imperative for success of community pharmacy

Achieving the community pharmacy vision necessitates legal adjustments and additional funding beyond recent boosts, the pharmacy vision document...